Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 577 of 6351
-
New 6-Month TB drug combo tested in diabetic patients
Disease control Not yet recruitingThe treatment of rifampicin-resistant/multidrug-resistant pulmonary tuberculosis (RR-TB) is characterized by a long treatment course, a high incidence of adverse reactions, a low cure rate, and a high recurrence rate. This is related to the large number of drugs in the RR-TB trea…
Sponsor: Wuhan Pulmonary Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Robot brain surgery trial aims to boost recovery after stroke
Disease control Recruiting nowA nationwide, prospective, multicenter randomized controlled clinical trial to evaluate the therapeutic effects of the fiber tract-based artificial intelligence (AI) Robot Guiding System on the perioperative and long-term recovery of patients with moderate-volume basal ganglion h…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
MRNA therapy takes on Hard-to-Treat multiple myeloma
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Phase 1/2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New antibody therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Dual-Target CAR-T therapy takes on tough leukemia
Disease control Recruiting nowThis is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients
Phase 1 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug combo aims to fight tough lung cancer
Disease control Not yet recruitingThis is a single-arm, open-label, single-center phase II trial that will enroll 30 patients with limited-stage small-cell lung cancer to evaluate the safety and efficacy of adebrelimab combined with chemoradiotherapy followed by adebrelimab maintenance.
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Blood test hunts hidden cancer, drug aims to stop it returning
Disease control Recruiting nowThis is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatm…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New weekly shot aims to reverse fatty liver damage
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects. Subjects will be randomly assigned to UBT251 2mg-dose, 4mg-dose,6mg-dose and placebo groups. The entire trial cycle includes a…
Phase 2 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New dual CAR-T attack on tough leukemia shows early promise
Disease control Not yet recruitingThis study is a single-arm, open-label, prospective clinical trial, with patients suffering from refractory and relapsed acute myeloid leukemia as the subjects. It plans to enroll 10 cases to evaluate the safety and efficacy of sequential CD123+CLL-1 CAR-T cells followed by CD7 C…
Early phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could cheap supplements cut heart failure risks? large trial launches
Disease control Recruiting nowHeart failure is a common and serious condition. Despite rapid advancements in heart failure treatment, the prognosis remains severe. Smaller studies have shown that two simple, safe, and relatively inexpensive nutritional supplements-coenzyme Q10 and selenium-may reduce the risk…
Phase 3 • Sponsor: Tor Biering-Sørensen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
AI ultrasound aims to slash maternal deaths in ethiopia
Disease control Not yet recruitingMaternal and neonatal health remains one of the most pressing global health challenges, particularly in low- and middle-income countries (LMICs). Ethiopia continues to face a high burden, with maternal mortality estimated at 195 per 100,000 live births, neonatal mortality at 27 p…
Phase 4 • Sponsor: Tsinghua University • Aim: Disease control
Last updated Jun 26, 2026 16:28 UTC
-
Nerve-Zapping procedure could boost liver cancer therapy
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of combining endovascular denervation (EDN) with transarterial chemoembolization/ hepatic arterial infusion chemotherapy (TACE/HAIC) plus second-line immune-targeted therapy in patients with locally advanced h…
Phase 1/2 • Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Stomach cancer breakthrough: study seeks best Post-Surgery care for complete responders
Disease control Not yet recruitingThis study is to evaluate the efficacy and safety of different postoperative adjuvant regimens in patients with resectable adenocarcinoma of the esophagogastric junction who underwent radical surgery after neoadjuvant chemotherapy combined with immunotherapy and achieved pCR in p…
Phase 4 • Sponsor: Liaoning Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 14:31 UTC
-
Gene therapy trial targets tough T-Cell cancers
Disease control Recruiting nowBackground: Chemokine receptor 4 (CCR4) is a protein that is found on the surface of certain T-cell lymphoma cells and is common in mature T-cell cancers. White blood cells can be changed with molecules called anti-CCR4 to express a chimeric antigen receptors (CAR), which is a m…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Gene-Tailored therapy could be Game-Changer for rare cancer patients
Knowledge-focused Recruiting nowRare cancers, defined by an incidence of fewer than 6 cases per 100,000 persons per year, constitute nearly 25% of adult malignancies. They are associated with poor patient outcomes due to incomplete biological understanding and inadequate representation in clinical trials. To ad…
Sponsor: German Cancer Research Center • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Engineered immune cells take on sarcoma in early trial
Disease control Recruiting nowTo find a recommended dose of attIL2-TIL cell therapy that can be given to participant with either relapsed or metastatic sarcomas (has come back or spread to other parts of the body, respectively). To further test the dose found in Part A to see if it can help to control liposa…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Heart-Shaping device could offer new hope for heart failure patients
Disease control Recruiting nowA prospective, multi-center randomized trial comparing the Revivent System plus GDMT to GDMT alone. A total of approximately 135 subjects will be randomized in a 2:1 allocation ratio (90 treatment and 45 control), with approximately 128 evaluable patients and assuming 5% loss to …
Sponsor: BioVentrix • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug trial aims to tame gut disease in kids
Disease control Recruiting nowThe aim of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of filgotinib as a treatment for UC in children and adolescents aged from 8 to less than 18 years. Approximately 80 subjects from 8 to \<18 years of age with moderately to severely…
Phase 3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New vaccine aims to stop pneumococcal bacteria in Kids' noses
Vaccine Recruiting nowThe goal of this clinical trial is to evaluate whether the wSp vaccine can prevent nasopharyngeal colonization by pneumococcal bacteria in healthy young children who have received routine PCV15 or PCV20 vaccination. The main questions it aims to answer are: Does wSp vaccine red…
Phase 2 • Sponsor: Serum Life Science Europe GmbH • Aim: Vaccine
Last updated Jun 27, 2026 13:00 UTC
-
Gene therapy injection aims to save sight in rare eye disease
Disease control Recruiting nowThe purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 admi…
Phase 1/2 • Sponsor: AAVantgarde Bio Srl • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC